Avanos Medical, Inc.

Good day and welcome to the Avanos Second Quarter 2021 Earnings Conference Call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing star then zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, press star then one on a touch-tone phone. To withdraw your question, press star then two. Please note this event is being recorded. I would now like to turn the conference over to Dave Crawford, Vice President of Investor Relations. Please go ahead.

Good morning, everyone, and thanks for joining us. It's my pleasure to welcome you to the Avidos 2021 Second Quarter Earnings Conference Call. With me this morning are Joe Woody, CEO and Michael Greiner, Senior Vice President and CFO. Joe will begin with an update on our quarter and then discuss our business environment and progress towards our 2021 priorities. Then Michael will review our second quarter results and update our 2021 planning assumptions. We will finish the call with Q&A. A presentation for today's call is available on the investor section of our website, Avanos.com. As a reminder, our comments today contain forward-looking statements related to the company, our expected performance, and economic conditions and our industry. No assurance can be given as to the future financial results. Actual results could differ materially from those in forward-looking statements. For more information about forward-looking statements and the risk factors that could influence future results, please see today's press release and the risk factors described in our filings with the SEC. Additionally, we will be referring to adjusted results in Outlook. The press release has information on these adjustments and reconciliations to comparable GAAP financial measures. Now, I'll turn the call over to Joe.

Thanks, Dave. Good morning, everyone, and thank you for your interest in Avanos. As we move into the second half of the year, I'm encouraged by our commercial teams' start to the year and the continued resiliency as they respond to the challenging dynamics brought on by the pandemic. Across our enterprise, we remain focused on getting patients back to the things that matter as we meet the needs of our customers. I will begin with a brief review of our results for the quarter before discussing the current environment and our progress against our 2021 priorities. Sales increased 14% for the quarter to $186 million while we earned 21 cents of adjusted diluted earnings per share. Our sales results were at the high end of our planning assumption. We not only benefited from the return of elective procedures, but more importantly, executed well against our growth initiatives. Performance for the quarter fell short of our expectations within our manufacturing and distribution footprint, negatively impacting gross margin for the quarter. These higher costs are temporary impacts to our business, primarily pandemic-driven, being seen across industries and do not indicate a permanent change to our operating structure. My management team and I have made this our top priority, and I'm confident we will show meaningful progress in the second half of the year. Michael will expand further on the steps we're taking in his remarks. I'm pleased with our team's execution in finding additional efficiencies throughout the business to reduce operating expenses. Teams are finding ways to increase productivity and lower our cost structure, which not only is assisting in offsetting some of our in-year gross margin headwinds, but also is positioning us to deliver on our commitment of SG&A as a percentage of revenue, being less than 40% on a go-forward basis. With that as a background, I'll discuss our market environment and update you on progress against our 2021 priorities, starting with how we are strengthening our growth profile. As I mentioned in our last earnings call, we began the quarter with increasing top-line momentum across our pain management franchise as elective procedures began to re-accelerate. Momentum continued throughout the quarter, and we saw the fastest acceleration in Cool Leaf and Game Ready, where outpatient procedures continued to recover faster than procedures performed within the hospital. Sales for both of these therapies eclipsed the pre-pandemic second quarter of 2019. While the recovery in OnQ has trailed our other pain therapies, we delivered sequential sales improvement throughout the quarter. Based on the gradual increase in procedures and conversations with our surgeons and hospital administrators, we continue to believe inpatient procedural volume will likely remain below its full potential until the end of the year. As we move into the second half of the year, we continue to build on our solid foundation to accelerate growth across pain management. For Cool-Leaf, we're planning to launch the next generation of Cool-Leaf cooled radio frequency probe kits. The new probes will make it easier for physicians to perform Cool-Leaf procedures while maintaining our premium look and feel. The new probes will also be more efficient for us to manufacture and deliver scalability, thus improving Cool-Leaf's already high gross margin. Combined with the launch of our new generator last year, our new probe kits strengthen our CoolRF leadership position. With respect to OnQ, we continue to see positive results from our channel partnership agreements where we are leveraging orthopedic sales partners to gain access to orthopedic surgeons. In an effort to differentiate ourselves from other pump manufacturers, in the coming months we'll be launching PainBlock Pro, a data collection and patient engagement app that will allow physicians to track their patients' recovery and understand their satisfaction levels and opioid consumption in real time without needing to speak with patients. PainBlock Pro will also help us engage patients and improve their experience by providing education about the pump and the ability for us to answer their questions. We will be the only pump company to offer both data collection and patient engagement to this extent. Finally, we continue to leverage our exclusive relationship with Leiters to further solidify our customer base. Shifting to chronic care, the positive trend across our digestive health franchise continues. We maintain double-digit growth across our Neomed franchise, while our standard of care strategy for CorePak is accelerating sales of our CoreTrack hardware to record levels. In respiratory health, sales were down as expected given the prior year pandemic tailwind. Finally, we continue to execute on our international expansion opportunities. Our market development initiatives focused on the clinical benefits of our therapies continue to pay dividends, and we are bolstering the growth of recently acquired products through our global footprint. While growth of the quarter was muted given the pandemic benefit last year, we delivered results at the high end of our expectations. Our second area focuses on gross and operating margin expansion. As I noted earlier, it is imperative that we begin to recapture gross margin loss since the start of the pandemic. Last year, we took the necessary steps to protect our employees from the pandemic and expand manufacturing of products to treat COVID patients. We responded well when presented with these challenges, but now need to address the inefficiencies and costs that arose out of our manufacturing sites. In addition, this year we have made a short-term trade-off to capture market share for our Neomid product family at the expense of higher freight costs to ensure that we take full advantage of its growth potential. These short-term cost increases will allow us to maximize the long-term investment of our Neomid acquisition, but have obviously created some in-year headwinds on gross margin that we did not anticipate coming into the year. Our continued cost discipline and emphasis on driving efficiencies in spending continues to produce results. I'm seeing a cultural shift in how our teams examine investments and make the necessary tradeoffs to achieve the best value for our spending. Improved efficiency also carried over into improved management of working capital, which helps drive a return to positive free cash flow in the quarter. We're on target for our third priority to begin generating consistent, repeatable free cash flow and continue to expect significant free cash flow acceleration in the second half as we await receipt of tax refunds we highlighted on prior calls coupled with our improved operating results and working capital discipline. Our last priority for the year focuses on capital deployment. Our M&A pipeline remains healthy and we are engaged in active dialogue with a number of potential tuck-in targets which would leverage our existing footprint. generate synergies, and enhance our top-line growth profile. M&A is a priority for us, but we will remain disciplined on identifying targets that meet both our strategic initiatives as well as exceed our financial hurdles, ensuring we generate a strong return on capital. Lastly, as a follow-up to the DOJ investigation we updated you on last quarter, in early July we entered into a deferred prosecution agreement with the United States Department of Justice that resolves the DOJ's criminal investigation related to the company's microcooled surgical gowns, which are part of the SNIP business we divested more than three years ago. As part of the agreement, we paid $22.2 million in line with the expectations we previously communicated. I want to assure our customers and our team members that we will continue to maintain robust compliance and quality programs and will continue to enhance them through new and revised policies, procedures, and training requirements. In conclusion, we remain well-positioned to advance our strategies across each of these four areas of value creation as our focus on execution remains strong. This, along with our market-leading portfolio, gives me confidence we can successfully deliver on our 2021 priorities. Now, I'll turn the call over to Michael.

Thanks, Joe. And as you noted, we remain in a challenging environment, especially with regards to supply chain operations. and yet the team continues to find ways to overcome these challenges. Now let's begin with a review of our second quarter results. Total sales of 186 million increased 14% compared to last year. We saw 13% increase in volume and a 1% benefit from favorable exchange rates. Unfavorable price offset sales by 1% as we saw price movement return within our normal range after slightly higher than normal price impact last quarter. Given the $10 million pandemic-related tailwind for respiratory health in 2020, chronic care sales declined 4% to $116 million in the quarter. Adjusting for the 2020 tailwind, respiratory health sales would have been down slightly for the quarter as we saw hospitals draw down their inventory of closed suction catheters and other related products as pandemic-related hospitalizations significantly declined. Although a new wave of pandemic-related hospitalizations appears to be upon us through July, We have not yet experienced material acceleration of orders from distributors or hospitals. Our planning assumption for respiratory health in the second half of 2021 does not include additional benefit from the pandemic, and we also expect a normal start to cold and flu season. Shifting to digestive health, we saw above normal growth as we experienced some pandemic-related disruption last year for our legacy Mickey franchise, providing a favorable comparison for this year. Neomed once again grew double digits from the continuation of conversions to our NFIT technology. Moving to pain management, we delivered 70 million of sales, 62% higher compared to the prior year, driven by the favorable prior year comparison resulting from the cancellation of elective procedures due to the pandemic. As Joe highlighted, growth has returned faster for our Cool Leaf and Game Ready therapies. Both of these therapies saw sales growth ahead of their pre-pandemic level, for the second quarter of 2019. With respect to on-queue, though the recovery for the therapy has trailed Cool Leaf and Game Ready, we continue to see the average day rate of sales increase on a monthly basis for the quarter. Sales through lighters and new customers using them as a pre-filler again increased by double digits as our partnership with lighters continues to benefit customers as a pre-fill option. Finally, despite a difficult prior year comparison, International organic sales grew at a low single-digit rate for the quarter. Sales did, however, benefit roughly $1 million due to the timing of shipments to distributors taking place at the end of June that were originally scheduled for early July. Moving down the income statement, adjusted gross margin decreased to 51% compared to 56% last year. As we indicated on our previous earnings call and as Joe noted earlier, Gross margin was expected to be impacted due to higher transportation costs to bring NeoMed products from China to the U.S. to meet customer demand. In addition, we continue to have inefficiencies at our manufacturing plants, in part for the safety precautions to protect our employees from the pandemic, as well as additional employees we hired during the pandemic at our plants. These factors have resulted in less productivity, higher overhead costs, and increased waste in recent quarters. While we saw improved mix given the increase in pain management sales, these headwinds had us behind our gross margin expectation for the quarter. Looking at the second half of the year, we continue to expect adjusted gross margin to significantly improve based on some of the following factors. First, we expect a continued benefit from our sales mix as sequential growth continues with pain management while we anticipate that demand for our respiratory health products will remain at normalized pre-COVID levels. This favorability will be magnified in the fourth quarter as we anticipate the normal seasonal uplift in our pain management franchise. Second, we will see a meaningful decrease in air freight costs versus the first half of the year. Although the anticipated benefit will be less than originally planned in the second half, given that higher transportation costs for ocean freight are still relevant for our NeoMed product family. Additionally, to ensure we achieve higher gross margin in the second half, In July, we have initiated several steps to return our facilities to pre-pandemic efficiency levels. We have recently reduced the number of employees that are manufacturing plants by approximately 10% to return employment at our facilities to pre-pandemic levels. We are also taking steps to reduce waste and scrap levels and are working with our commercial teams to sell slow-moving inventory to reduce the increase in write-offs incurred recently. Finally, in order to offset some of the inflationary pressures across our supply chain, we are informing some customers of price increases beginning later this year. Due to the slow start for the year, our adjusted gross margins are now expected to be slightly below our 2020 margin levels. To offset this reduced gross margin level, we are reducing operating expenses in order to maintain our commitment for operating margin improvement for the year. Now, turning your attention to some bottom line financial metrics. Adjusted operating profit totaled $15 million compared to $13 million in the prior year. Performance was primarily driven by higher sales volume, which was partially offset by the lower adjusted gross margin I just reviewed. Adjusted EBITDA totaled $20 million compared to $19 million last year, and adjusted net income totaled $10 million compared to $6 million a year ago, as we earned $0.21 of adjusted diluted earnings per share. Turning to the balance sheet and cash flow statement, as Joe highlighted, we achieved positive free cash flow absent the receipt of any of our CARES Act refunds. Keeping a healthy balance sheet and generating meaningful free cash flow remains a key go-forward priority. Our balance sheet is solid and continues to provide us with strategic flexibility as we enter the quarter with $100 million of cash on hand and $165 million of debt outstanding on our revolving credit facility, an improvement of $10 million versus the end of the previous quarter due to a small repayment. Free cash flow represented an inflow of $10 million enhanced by improved working capital. Finally, While some unpredictability of the coronavirus remains, we are reaffirming net sales on a constant currency basis to increase 2% to 4% compared to the prior year. However, due to increased manufacturing and transportation costs, partially offset by operating expense savings, we are reducing the top end of our earnings guidance. We now expect to earn between $1.10 and $1.20 of adjusted diluted earnings per share. In closing, we are off to a solid start at the halfway point of the year, I'm confident in our ability to execute our strategy and to take the necessary steps to drive gross and operating margin improvement and deliver significant free cash flow in the second half of the year. Operator, please open the line for questions.

We will now begin the question and answer session.

To ask a question, press star then 1 on a touch-tone phone. If you're using a speakerphone, please pick up your headset before pressing the keys. To withdraw your question, press stars and two.

At this time, we will pause momentarily to assemble our roster. And the first question comes from Matthew Michon with Keep.

Please go ahead.

Good morning, guys. Morning. I just first wanted to start with NeoMed. I mean, this is an acquisition you made a couple of years ago. It seems to be doing very well from an annual live sales run rate, but the gross margin still has been a problem. Can you kind of walk us through kind of where you started with NeoMed, where you're at now, and kind of how you think about the gross margin progression for that business?

Yeah, Matt, I'll say a couple things, and as always, Michael might jump in, but this has been a highly successful acquisition for us. It grows double-digit, did again, in this quarter the other thing going on alongside of this is that there's a conversion of called the infant conversion which is a global standard happening it really need to be complete by customers moving into next year and so what you're seeing from us is that we have we manufacture in China is during the pandemic increased transportation rates particularly air where we need to get the product over we've made a decision to ship air and so that we can get the conversions. They have a timeline, our customers, that they're up against, and they're going to definitely benefit us going forward as we get the repeat sales associated with that. But it's obviously a headwind to our gross margin. So generally, when I think of the model, I think once we get through the pandemic and some of these temporal items on the gross margin, we're going to be in really good shape with all the metrics that we put in place, a lot like we were pleased with, for example, with CordTrack. But Michael, I don't know if you want to add anything.

Yeah, no, I think we're making choices here, to Joe's point, to secure these conversions. Even with these headwinds that are impacting gross margin, when we look at our model, the DCF is still very attractive for this business over the forthcoming few years. We never modeled NeoMed, even from the beginning, to have gross margins in excess of our consolidated gross margin set. So NeoMed, when it's in its more normalized state, Matt, will still be below the company level, slightly below the company level gross margins. It's significantly below right now because of these freight cost headwinds, but even in a normalized state, NeoMed was never modeled to be above our company level gross margin, if that's helpful.

Yeah, but just going back to the question, when you bought it, I think it was an annualized run rate of about $40 million. Once you finish this in-fit conversion, how big of a chunk of business is NeoMed for you guys?

I mean, so I see it like a lever, you know, similar to international business, but more like Cool Leaf, where it's a similar size and growing double digit and has some consistency for that in the next couple of years. So we like it quite a bit.

Okay. And then just shifting over to Cool Leaf, the new probes that you're going to be rolling out next year, I mean, it's at a higher gross margin, but does that more effectively allow doctors to do this in the ASC or the physician office?

We have some of that later on. This is not, I think, what we were talking about in the prepared remarks. And you'll see both upgrade opportunities and new business, we think, driven out of this introduction.

Okay. And then just lastly on the gross margin side, I realize there's a lot going on and people are across the board talking about, you know, the headwinds and freight and manufacturing and efficiencies. But when you say significant improvement into 2H, Can you give us a sense of what that means? I know gross margins are now going to be below last year, but what should we rearrange of what to expect around improvement?

Yeah, I'm going to tee up a couple things, and then Michael, I think, is going to walk you through a little bit of the way we look at H2 and think about it. And we did talk about this on our on our previous calls and said that we thought Q2, you know, we'd still see headwinds and gross margin. Obviously, we saw a little bit more than anticipated. When you think about, we were just talking about NEOMED, really half the tailwind was reflected in NEOMED, which is why we're saying, look, this is a temporal and not a fundamental change in our business. And I think that there are some things because of the fact that we're dealing with China and air there, air freight, and some of the things we did in Mexico, reminding everybody that we had investments in our plans. We were dealing with obviously the Mexican government and employees, but also built out the closed suction line so that we wouldn't experience a deferred debt defense, a DPA, from the government. And so when you put that together, you sort of have two unique situations. That said, we've got a completely different line of sight for the second half. I think Michael wants to kind of take folks through that.

Yeah, Matt, we were, Joe alluded to, we were about 200 basis points in Q2 below where we thought we'd be. So that's kind of a starting point. When we think about where we're going in the back half of the year, we have a couple things that are just part of the map. So we won't have the revaluation impacts that we had in the first half of the year. That's about 200 basis points. Price mix, we anticipate, will improve by about 150 basis points. Part of that is some of these price increases that were passing along with our customers. Some of it is the continued slow but steady improvement in our on-cube business that we've been seeing, the day rates that we referenced. Another 200 basis points relates to plant performance, some related to the reduction in the workforce by 10%, as well as reducing the write-offs that we've incurred in the first half of the year. And then another 50 basis points on freight, primarily to neomed now that we thought would be a little bit higher but we're seeing is increased freight from a from a water lane standpoint but obviously significantly cheaper than the air freight that we have been doing so that gives you about 600 plus basis points of very specific items and then we have some other items that we're working through as well so that kind of walks you your question was how significant we think very significant Unfortunately, because Q2 is 200 basis points below, we're going to be within or slightly below where we were in 2020, which obviously was not our plan coming into the year.

Okay, understood. Thank you for quantifying that.

Thanks, Matt.

The next question comes from Chris Cooley with Stevens. Please go ahead. Morning, Chris.

Hi. Hey, good morning. This is actually Ross Osborne for Chris. Okay, Ross. Thanks for taking my questions. So starting with the top line, can you kind of just walk us through the puts and takes of what you guys assume in the lower and upper bound of revenue guidance?

Yeah, so I'll just maybe say a couple things up front about just the quarter, and then Michael might want to comment a little bit more on what we see going forward. and the guidance piece, but we saw continued sequential progression in our pain business more so in Game Ready and Cooley, and we think that's because of obviously the hospital outpatient department and where they're performed, and we've talked a little bit about Oncube, although that was slightly below 19, it did also progress, but then some of the procedures in the hospitals haven't come back as quickly as they have in the ambulatory surgical setting. We think that chronic care, in terms of our plan internally, has a trajectory for the mid-single-digit for the full year that we talk about in that business. And then, obviously, we're seeing some of the comparator issues in respiratory and closed suction from COVID last year. So, as a specific example, before I hand off to Michael, I think everyone should be thinking about $12 million. you know that was part of respiratory sales in 2020 that that won't be a part of 2021 that goes into some of our thinking anyway about the guidance for the second half so Michael yeah I think you know the upside to Joe's point would include on cue continuing to improve and accelerate as electives come back while on the respiratory side we have a normal respiratory season

You know to the downside you would see You know on cue kind of level off here not continue to have electives come back because of the variants while treatment protocols You're no longer necessary to look for closed suction catheterization So we would continue to get a normalized respiratory, but we wouldn't get that that extra benefit. So we'd have normal respiratory and you know, on cue coming back down because electives are coming back down, that would put us more on the low side. On the upside, both of those are actually moving forward, you know, where we get hospitalization and closed-section catheter being part of that treatment protocol while the electives don't pull back like they did in the previous period last year.

Got it. That's really helpful. And then kind of just a bigger picture question. So guidance for full years, 2% to 4%, X hundred bits from currency. I guess what's holding back top line from approaching mid-single digits growth on an organic basis?

Yes, I think Michael touched on some of it. We should touch on it just a little bit again. We've got a $12 million comparator in respiratory that won't be with us. That's one thing. And then there's a little bit of uncertainty still, although we have not seen anything this regionalized discussion of electives being affected by the Delta, you know, the Delta variant, and how that also may impact any of our international business, which, by the way, is, you know, primarily chronic care. So, I mean, there's, you know, obviously can be affected by that being less of an impact, but certainly the respiratory chronic care piece is there.

And, Ross, I mean, it's a fair question, and if you do look at 2019 Q2, versus 2021 Q2, we do have organic growth of over 7%. So that does get you in that mid-single digits. I think we're just being appropriately cautious in the back half of the year, just not knowing exactly how the new variant's gonna play out and exactly how hospitals and other treatment protocols will react to that.

Okay, fair enough. And then just kind of a clarifying question. make sure you have the cadence right for the rest of the year. So lower gross margin, and then that will hopefully be offset by greater OpEx reductions.

That's right.

Okay.

That's right.

Got it. Thank you, guys.

And just to clarify on that question, Ross, you know, we took down the top end of guidance, not necessarily indicating that $1.17, $1.18 is not achievable, right? So $1.10 to $1.25 is We'd like to, not we, but what kind of happens in the community is you take the midpoint, that gives you $1.17. Our move from $1.25, $1.20 was just signaling $1.25 is not possible. That doesn't mean that $1.17, $1.18 is still not possible. We're trying to be intellectually consistent with the lower gross margins. The OpEx is going to help offset that, but with that gross margin headwind, $1.25 just isn't something that seems to be in the cards. That does not mean that $1.17, $1.18 can't be achieved.

Got it. Thank you. Thanks, Rob.

As a reminder, if you have a question, press star then 1 to join the queue. The next question comes from Robby Misra with Berenberg. Please go ahead. Hi, good morning, Robby.

Hey, good morning. Thanks for taking the question, everyone. Yeah. One, if I can just start on OnQ and the elective rebound, are you still kind of under the current parameters? Is this a business that can kind of finally return to growth for the full year? Or do we need – it sounds like you're a little bit more cautious on the elective outlook there. If you could help me kind of think about how to kind of model this thing going forward from what's implied from a procedural growth perspective.

Yeah, that would be the big driver is the electives being the biggest lever as to growth. We're seeing our initiatives work. A couple that we're really focused on is the channel partnerships with large orthopedic 1099 groups. We're happy with what we're seeing on the AMBIT acquisition and how we're now having an electric pump offering, and that's working well for us from a portfolio perspective. The PainBlock Pro from some of the initial... roll out of that. We're seeing success and customers are very interested in that, being able to track the outcomes of not only our product but against other approaches to pain management. And, you know, we're happy with, you know, what Bill Hayden has done under his leadership to kind of point that business in the right direction. And then, obviously, we've just come out of a strategic board meeting where we've talked about some future products, you know, in particular the electronic nerve block that we think can be a big game changer in that space. So we're happy with where we are. We think, again, the biggest lever on whether or not you get the growth and how fast it comes is the elective procedure. So to the extent Delta doesn't quell a lot of things, then we can do better.

And, Robby, electives has become this big word in med device over the last 16 months. When you look at game ready and Cooley, as Joe talked about in the prepared remarks, those are back and above where we were. So that definition of electives has worked, you know, well, and we've captured all that's appropriate there. But obviously, remember, it's generally for very specific types of procedures. Multi-day stay often are definitely multi-day recovery. And so, you know, those types of electives have not come back as quickly.

Okay, great. And then just on the gross margin, sorry, don't want to keep harping on it, but I'm curious, your mix kind of shift this quarter was pretty significantly tilted towards the pain management business, and you're calling out this NeoMed kind of higher freight costs. Just help us calibrate maybe. I don't know if she called out kind of the actual quantification of that freight cost. I mean, if that wasn't there, would you have been – at that kind of, you know, 53 sounds like where you were targeting internally? Or was there more to it than that? Because I would assume that the mixed shift into pain management would have more than offset some of that.

Right. So the freight was a portion of it. It basically offset the mixed shift. And then, to your point, we had an additional amount of plant performance underperformance from an efficiency standpoint that was the additional 100 or so basis points that we underperformed by So you are right, freight was a portion of it, but we also then had the plant underperformance in 2Q, which we've now done some steps in mid-July to rectify for.

Great. And maybe one last one, Joe, just on kind of opioid safety and that project there. What should we be kind of thinking about here for the rest of the year, or is this now a 2022 event?

I'm sorry, I didn't hear the first part of your question, Rob.

The novel technology, the opioid product.

The go, yes. So actually, we're actually rolling that product out now. We'll continue throughout the second half. And so this will be something that as we end the year going to 22, we'll be rolling, Pain Block Pro it's called.

Okay, that is the software that, okay, got it, okay.

Yep. Thank you, Robbie.

As we have no further questions, this concludes our question and answer session. I will now turn the conference back over to Joe Woody for any closing remarks.

Thank you. As many of you may know and have been talking to Dave Crawford after nine years from the spin of Halyard to Avanos, Dave is going to be moving on. He's been our treasurer and obviously our head of investor relations We definitely want to thank him for his service to the company, but I would say that his business guidance and consultation and partnership have really been outstanding. And so we wish Dave the best, and we'll definitely stay in touch with him. And I thank all of you for your continued interest in Avanos. We continue to execute well in an uncertain environment. We remain really committed to creating shareholder value. I'm confident we've got the right priorities detailed. combined with our portfolio, and we think we're in attractive markets. We're positioned well for sales growth, margin expansion, and the free cash flow that we want to generate. So look forward to chatting as we go forward. Thank you all.

The conference is now concluded. Thank you for attending today's presentation. You may now disconnect.